Medpace (NASDAQ:MEDP) CEO August Troendle Sells 15,971 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 15,971 shares of the company’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $620.84, for a total transaction of $9,915,435.64. Following the transaction, the chief executive officer owned 523,923 shares of the company’s stock, valued at $325,272,355.32. This represents a 2.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Medpace Trading Down 0.2%

MEDP traded down $1.15 during midday trading on Thursday, hitting $615.29. 221,328 shares of the company traded hands, compared to its average volume of 333,335. The business has a 50 day simple moving average of $582.78 and a two-hundred day simple moving average of $508.65. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The company has a market capitalization of $17.17 billion, a price-to-earnings ratio of 36.07, a PEG ratio of 2.77 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. The firm had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company’s revenue for the quarter was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities research analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company lifted its position in Medpace by 38.9% during the second quarter. The Manufacturers Life Insurance Company now owns 20,043 shares of the company’s stock worth $10,615,000 after buying an additional 5,610 shares in the last quarter. Sequoia Financial Advisors LLC grew its holdings in Medpace by 8.2% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 1,108 shares of the company’s stock valued at $587,000 after buying an additional 84 shares in the last quarter. Tidal Investments LLC grew its holdings in Medpace by 8.0% in the 2nd quarter. Tidal Investments LLC now owns 6,155 shares of the company’s stock valued at $3,260,000 after buying an additional 458 shares in the last quarter. Archford Capital Strategies LLC increased its stake in shares of Medpace by 5.4% in the 2nd quarter. Archford Capital Strategies LLC now owns 1,658 shares of the company’s stock worth $878,000 after acquiring an additional 85 shares during the last quarter. Finally, NewEdge Advisors LLC increased its stake in shares of Medpace by 3.9% in the 2nd quarter. NewEdge Advisors LLC now owns 2,865 shares of the company’s stock worth $1,517,000 after acquiring an additional 108 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Royal Bank Of Canada raised their target price on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Weiss Ratings raised Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. BMO Capital Markets raised their price objective on Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a report on Friday, July 24th. Jefferies Financial Group reaffirmed a “hold” rating on shares of Medpace in a research note on Monday. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $535.00 target price on shares of Medpace in a report on Thursday, July 23rd. Three analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, Medpace has an average rating of “Hold” and an average price target of $595.20.

About Medpace

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.